Halozyme to Participate at Upcoming Investor Conferences
Halozyme Therapeutics (NASDAQ: HALO) announced its participation in three upcoming investor conferences in September 2025. CEO Dr. Helen Torley and VP of Investor Relations Tram Bui will represent the company.
The schedule includes presentations at the Wells Fargo Healthcare Conference in Boston on September 4, the Morgan Stanley Global Healthcare Conference in New York on September 8, and the H.C. Wainwright Global Investment Conference in New York on September 9. Live audio webcasts will be available on Halozyme's website with 90-day replay access.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato la sua partecipazione a tre conferenze per investitori previste per settembre 2025. La CEO, Dr.ssa Helen Torley, e la VP Investor Relations, Tram Bui, rappresenteranno la società.
Il calendario prevede interventi al Wells Fargo Healthcare Conference a Boston il 4 settembre, al Morgan Stanley Global Healthcare Conference a New York l'8 settembre e all'H.C. Wainwright Global Investment Conference a New York il 9 settembre. I webcast audio in diretta saranno disponibili sul sito di Halozyme con replay accessibile per 90 giorni.
Halozyme Therapeutics (NASDAQ: HALO) anunció su participación en tres conferencias para inversores programadas para septiembre de 2025. La CEO, Dra. Helen Torley, y la VP de Relaciones con Inversores, Tram Bui, representarán a la compañía.
El calendario incluye presentaciones en la Wells Fargo Healthcare Conference en Boston el 4 de septiembre, en la Morgan Stanley Global Healthcare Conference en Nueva York el 8 de septiembre y en la H.C. Wainwright Global Investment Conference en Nueva York el 9 de septiembre. Habrá retransmisiones de audio en directo en la web de Halozyme con acceso a la repetición durante 90 días.
Halozyme Therapeutics (NASDAQ: HALO)는 2025년 9월에 개최되는 3개의 투자자 컨퍼런스에 참가한다고 발표했습니다. CEO 헬렌 토클리 박사와 IR 담당 부사장 트램 부이가 회사를 대표합니다.
일정은 9월 4일 보스턴에서 열리는 Wells Fargo Healthcare Conference, 9월 8일 뉴욕에서 열리는 Morgan Stanley Global Healthcare Conference, 9월 9일 뉴욕에서 열리는 H.C. Wainwright Global Investment Conference에서의 발표를 포함합니다. 라이브 오디오 웹캐스트는 Halozyme 웹사이트에서 제공되며 90일간 재청취 가능합니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé sa participation à trois conférences investisseurs prévues en septembre 2025. La CEO, Dr Helen Torley, et la VP des relations investisseurs, Tram Bui, représenteront la société.
Le programme inclut des présentations lors de la Wells Fargo Healthcare Conference à Boston le 4 septembre, de la Morgan Stanley Global Healthcare Conference à New York le 8 septembre et de la H.C. Wainwright Global Investment Conference à New York le 9 septembre. Des webcasts audio en direct seront disponibles sur le site de Halozyme avec un accès au replay pendant 90 jours.
Halozyme Therapeutics (NASDAQ: HALO) gab bekannt, dass das Unternehmen an drei Investorenkonferenzen im September 2025 teilnehmen wird. CEO Dr. Helen Torley und die VP Investor Relations, Tram Bui, werden die Firma vertreten.
Der Zeitplan umfasst Präsentationen auf der Wells Fargo Healthcare Conference in Boston am 4. September, der Morgan Stanley Global Healthcare Conference in New York am 8. September und der H.C. Wainwright Global Investment Conference in New York am 9. September. Live-Audio-Webcasts sind auf der Halozyme-Website verfügbar und können 90 Tage lang nachgehört werden.
- None.
- None.
Details on the Company's participation are as follows:
Event: | 2025 Wells Fargo Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Presentation Date: | Thursday, September 4, 2025 | |||
Presentation Time: | 10:30am PT / 1:30pm ET | |||
Location: | ||||
Event: | Morgan Stanley 23rd Annual Global Healthcare Conference | |||
Format: | Fireside Chat and 1x1 Meetings | |||
Date: | Monday, September 8, 2025 | |||
Presentation Time: | 4:45am PT / 7:45am ET | |||
Location: | ||||
Event: |
H.C. Wainwright 27th Annual Global Investment Conference | |||
Format: | 1x1 Meetings | |||
Date: | Tuesday, September 9, 2025 | |||
Location: |
A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Sydney Charlton
Teneo
917-972-8407
sydney.charlton@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-at-upcoming-investor-conferences-302540470.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When is Halozyme (HALO) presenting at the Wells Fargo Healthcare Conference 2025?
What time is Halozyme's presentation at the Morgan Stanley Healthcare Conference 2025?
Who will represent Halozyme at the 2025 investor conferences?
How can investors access Halozyme's conference presentations?
